Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Hua who wrote (1082)	5/22/1998 8:16:00 AM
From: Joey Two-Cents	Respond to of 2135

<Ron, I intend to short more ENMD tomorrow. The company and its hype is fading from spotlight. Don't know about 3 years, but in 3 months, I'd be surprised if ENMD trades above 18.> The market had decided $ 12 was a fair value for this stock on which I understood the cancer treatment news had been published in some other periodicals in 1997. Even when those stories were published in 1997 the stock only went to $ 15. In this go-go investment era, the type of investor to jump on a stock that is up 700% is probally not the most patient of investors and will sell when the next NEOT or KTEL emerges. It was good to see ENMD management speak honestly and openly on the chances of a drug being tested and manufactured anytime soon. However from the CNBC & othe rmedia outlets the hype continued for days (probally some reporter bought at $ 86 trying to recoup their losses) until they could no longer pump it a found something else to hype like NEOT (which mgt also said was an old announcement).